Pharmaceutical major Cipla posted a 10% year-on-year increase in consolidated net profit at Rs 1,298 crore for the quarter ended June 30, 2025, aided by solid demand in domestic and select international markets. The company had reported a net profit of Rs 1,178 crore in the same period last year.Revenue from operations stood at Rs 6,957 crore for the first quarter of FY26, up from Rs 6,694 crore a year ago, the company said in a regulatory filing on Friday.Managing Director and Global CEO Umang Vohra said the “One-India” franchise expanded 6% YoY in Q1, with key prescription therapies outperforming market trends. He noted that Cipla’s trade generics segment had regained momentum and the company’s consumer health brands maintained their leadership.“Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front,” Vohra said.Sales in the Indian market rose to Rs 3,070 crore from Rs 2,898 crore a year earlier, while business in North America declined 7% to Rs 1,933 crore. The company attributed the dip to pricing pressure and portfolio dynamics.Revenue from emerging markets and Europe rose to Rs 861 crore, reflecting 11% growth over last year’s Rs 779 crore. Sales in Africa rose 14% to Rs 871 crore in the June quarter from Rs 766 crore in Q1 FY25.Cipla shares jumped 3.8% to close at Rs 1,543.80 on the BSE following the earnings report.